Filter posts

Deal Structures: More Options for Companies

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal …

Fireside Chats with Five CEOs Featured at Day Two of the BIO CEO & Investor Conference

Fireside Chat with John F. Milligan, PhD, President & COO, Gilead Sciences The first fireside …

Session Recap: “Trust Your Gut” – Therapeutic Opportunities from the Microbiome

Tuesday at the BIO CEO & Investor Conference kicked off with a Therapeutic Workshop titled, …

Celebrate Valentine's Day with Color Changing Flowers

Wouldn’t it be great if you could break the mold and give your special someone …

Ten Years of Therapeutic Venture Capital

What therapeutic areas have received the most funding in private drug companies over the last …

Session Recap: Digital Health—Early Successes for Investors and Biotech R&D Productivity

Digital health has the potential to improve the life science industry by combining traditional and …